| Management of Helicobacter pylori in patients with immune thrombocytopenia YAM Vanegas, P Vishnu Hämostaseologie 39 (03), 279-283, 2019 | 21 | 2019 |
| Handbook of hematologic malignancies DA Sallman, A Chaudhury, J Nguyen, L Zhang Springer Publishing Company, 2020 | 10 | 2020 |
| Post-transplant erythrocytosis refractory to ACE inhibitors and angiotensin receptor blockers P Vishnu, YM Vanegas, HM Wadei, CE Rivera Case Reports 2018, bcr-2018-224622, 2018 | 7 | 2018 |
| Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features B Dholaria, YAM Vanegas, N Diehl, AC Spaulding, S Visscher, HW Tun, ... Clinical Hematology International 2 (3), 117-124, 2020 | 4 | 2020 |
| Malignancy-induced lactic acidosis in adult lymphoma P Duriseti, YM Vanegas, BL Jaber, VS Balakrishnan, NE Madias Clinical Nephrology 95 (1), 1, 2021 | 3 | 2021 |
| Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: Concomitant occurrence of two molecularly distinct diseases YAM Vanegas, AGM Azzouqa, DM Menke, JM Foran, P Vishnu Hematology Reports 10 (3), 7658, 2018 | 3 | 2018 |
| Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma R Mohty, Y Moreno Vanegas, JC Chavez, MA Kharfan-Dabaja Expert Review of Anticancer Therapy 23 (2), 121-126, 2023 | 2 | 2023 |
| CAR-T cell therapies for B-cell lymphoid malignancies: identifying targets beyond CD19 YM Vanegas, R Mohty, ME Gadd, Y Luo, M Aljurf, H Qin, ... Hematology/Oncology and Stem Cell Therapy 15 (3), 8, 2022 | 2 | 2022 |
| Chemotherapy‐induced anaphylaxis and fatal anaphylaxis in the United States: Incidence and risk factors. L Bojanini, D Morgenstern‐Kaplan, I Carrillo‐Martin, YA Moreno Vanegas, ... Clinical & Experimental Allergy 51 (11), 2021 | 2 | 2021 |
| Delayed presentation of doxorubicin extravasation into pleural space: Case report and review of literature V Kazakova, YAM Vanegas, TA Torres, O Kozyreva Journal of Oncology Pharmacy Practice 27 (6), 1520-1527, 2021 | 2 | 2021 |
| Clinical Outcomes and Cost Analysis of Dose-Adjusted R-EPOCH Vs R-CHOP in Treatment of Diffuse Large B-Cell Lymphoma with High Risk Features B Dholaria, P Vishnu, YA Moreno-Vanegas, AC Spaulding, NN Diehl, ... Blood 132, 4790, 2018 | 2 | 2018 |
| U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity T Badar, YAM Vanegas, A Nanaa, JM Foran, A Al-Kali, A Mangaonkar, ... Blood cancer journal 13 (1), 149, 2023 | 1 | 2023 |
| Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes Y Moreno Vanegas, T Badar Cancer Management and Research, 3527-3538, 2022 | 1 | 2022 |
| Differential impact on survival in myeloid neoplasm patients with U2AF1 mutations Y Moreno Vanegas, A Nanaa, A Al-Kali, R He, HB Alkhateeb, MM Patnaik, ... Blood 140 (Supplement 1), 9602-9603, 2022 | 1 | 2022 |
| Decreased physical activity in autologous stem cell recipients leads to reduced QOL scores during hospitalization C Baldeo, YM Vanegas, S Khurana, M Iqbal, AG Azzouqa, T Sher, ... Blood 132, 5895, 2018 | 1 | 2018 |
| DA. R-EPOCH vs. R-CHOP for high-risk diffuse large B-cell lymphoma: The Mayo Clinic Florida Experience B Dholaria, P Vishnu, V Roy, HW Tun, T Sher, CE Rivera, S Ailawadhi, ... Blood 130, 1572, 2017 | 1 | 2017 |
| A Multicenter Analysis of Allogeneic Transplant Outcomes in Patients with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL) ZA Rahman, PB Koller, T Othman, RM Saliba, YAM Vanegas, R Mohty, ... Blood 142, 656, 2023 | | 2023 |
| Evaluation of Atrial Fibrillation Risk and Outcome after Allogeneic Transplantation Using an Artificial Intelligence ECG Algorithm and Echocardiographic Parameters in an MDS Cohort M Ballerini, M Heckman, L White, R Mohty, YV Moreno, H Alkhateeb, ... Blood 142, 2287, 2023 | | 2023 |
| IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A … R Mohty, Y Moreno Vanegas, MG Heckman, HB Alkhateeb, AP Hochwald, ... Blood 140 (Supplement 1), 4863-4864, 2022 | | 2022 |
| Incidence of and Risk Factors for Chemotherapy-Induced Anaphylaxis Agents in the United States L Bojanini, I Carrillo-Martin, YM Vanegas, L Cuervo-Pardo, R Zwiener, ... Journal of Allergy and Clinical Immunology 147 (2), AB18, 2021 | | 2021 |
Prakash VishnuMayo Clinic FloridaVerified email at mayo.edu
